Oxinas Partners Wealth Management LLC Makes New Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Oxinas Partners Wealth Management LLC bought a new stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 12,250 shares of the company’s stock, valued at approximately $122,000.

A number of other hedge funds have also recently made changes to their positions in RXRX. TB Alternative Assets Ltd. bought a new position in Recursion Pharmaceuticals in the first quarter worth approximately $706,000. Wedmont Private Capital grew its position in shares of Recursion Pharmaceuticals by 11.8% during the 1st quarter. Wedmont Private Capital now owns 18,943 shares of the company’s stock worth $172,000 after buying an additional 2,000 shares in the last quarter. Green Alpha Advisors LLC increased its stake in shares of Recursion Pharmaceuticals by 6.7% during the first quarter. Green Alpha Advisors LLC now owns 72,434 shares of the company’s stock valued at $722,000 after buying an additional 4,563 shares during the period. Vanguard Group Inc. raised its holdings in shares of Recursion Pharmaceuticals by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 15,665,210 shares of the company’s stock valued at $154,459,000 after acquiring an additional 158,376 shares in the last quarter. Finally, Mubadala Investment Co PJSC bought a new stake in shares of Recursion Pharmaceuticals in the fourth quarter valued at about $128,041,000. 89.06% of the stock is currently owned by institutional investors.

Insider Activity

In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 50,000 shares of the company’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $7.73, for a total transaction of $386,500.00. Following the completion of the transaction, the chief executive officer now directly owns 863,524 shares in the company, valued at $6,675,040.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $7.73, for a total transaction of $386,500.00. Following the completion of the sale, the chief executive officer now directly owns 863,524 shares in the company, valued at approximately $6,675,040.52. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 27th. The shares were sold at an average price of $7.21, for a total value of $43,260.00. Following the completion of the transaction, the chief operating officer now owns 535,457 shares in the company, valued at approximately $3,860,644.97. The disclosure for this sale can be found here. Insiders sold 247,359 shares of company stock worth $2,058,035 over the last three months. 15.75% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on RXRX. Needham & Company LLC reiterated a “buy” rating and issued a $17.00 price target on shares of Recursion Pharmaceuticals in a report on Tuesday, June 25th. KeyCorp lifted their target price on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Monday, March 4th.

Recursion Pharmaceuticals Stock Down 4.0 %

Shares of NASDAQ:RXRX traded down $0.30 during midday trading on Tuesday, reaching $7.16. The company’s stock had a trading volume of 6,072,266 shares, compared to its average volume of 6,273,782. The firm has a market capitalization of $1.70 billion, a PE ratio of -4.47 and a beta of 0.83. The stock has a fifty day moving average of $8.83 and a 200 day moving average of $9.91. Recursion Pharmaceuticals, Inc. has a twelve month low of $4.97 and a twelve month high of $16.75.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Thursday, May 9th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.04. The firm had revenue of $13.80 million during the quarter, compared to analyst estimates of $11.10 million. Recursion Pharmaceuticals had a negative net margin of 765.90% and a negative return on equity of 79.96%. The business’s quarterly revenue was up 14.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.34) EPS. Sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.6 earnings per share for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.